Showing 61-70 of 9431 results for "".
- Analysis: Antiepileptic Drugs Linked to Nearly One-Quarter of Global SJS/TEN Caseshttps://practicaldermatology.com/news/antiepileptic-drugs-linked-to-nearly-one-quarter-of-global-sjsten-cases-meta-analysis-finds/2487988/Antiepileptic drugs (AEDs) account for nearly one-quarter of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases reported worldwide, according to a systematic review and meta-analysis in JAMA Dermatology
- Analysis: Topical Corticosteroids Effective for Select Patients With DRESS Syndromehttps://practicaldermatology.com/news/analysis-data-support-topical-corticosteroids-for-select-patients-with-dress-syndrome/2487960/Topical corticosteroids may offer comparable short-term outcomes to systemic corticosteroids for selected hospitalized patients with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, according to a multicenter retrospective cohort study publi
- EV-Related Skin Toxic Effects Associated With Improved Survival in Urothelial Cancer: Analysishttps://practicaldermatology.com/news/ev-related-skin-toxic-effects-associated-with-improved-survival-in-urothelial-cancer/2487950/Cutaneous adverse events (cAEs) that develop during treatment with enfortumab vedotin (EV) may serve as a favorable prognostic marker in patients with locally advanced or metastatic urothelial carcinoma, according to a new study published online in
- GLP-1 Receptor Agonists Linked to Reduced Psoriasis Treatment Escalation in Type 2 Diabetics: Analysishttps://practicaldermatology.com/news/glp-1-receptor-agonists-linked-to-reduced-psoriasis-treatment-escalation-in-type-2-diabetics-analysis/2487939/Adults with psoriasis and type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were less likely to require escalation of psoriasis therapy than patients receiving most other antihyperglycemic medications, according to
- Study: Intentional Outdoor Tanning Common Among US Adults, Especially Young Womenhttps://practicaldermatology.com/news/intentional-outdoor-tanning-remains-common-among-us-adults-especially-young-women/2487924/Intentional outdoor tanning remains a common behavior among US adults, particularly younger women, according to a large cross-sectional analysis of nationally representative survey data published online in JAMA Dermatology.<
- Sanofi Halts Amlitelimab Development in Atopic Dermatitishttps://practicaldermatology.com/news/sanofi-halts-amlitelimab-development-in-atopic-dermatitis/2487921/Sanofi has announced it will discontinue the clinical development of amlitelimab for moderate-to-severe atopic dermatitis (AD), ending plans to submit the investigational therapy for global regulatory review after determining it would not provide a meaningful adva
- Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients With Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-demonstrates-consistent-efficacy-across-pediatric-and-adult-patients-with-atopic-dermatitis/2487900/Organon will present new data from a post hoc pooled analysis of the Phase 3 ADORING 1 and ADORING 2 trials at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis, Minnesota, showing that tapinarof (VTAMA) cream 1% produced early and consistent improvements in patients
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f
- SKNV Secures Exclusive Rights to Patented 5-FU/Calcipotriene Combination for Actinic Keratosishttps://practicaldermatology.com/news/sknv-secures-exclusive-rights-to-patented-5-fucalcipotriene-combination-for-actinic-keratosis/2487883/SKNV has obtained exclusive commercialization rights under a sublicense to a patent covering the combination of fluorouracil (5-FU) and calcipotriene, according to an announcement. The patented combination is currently avai
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://practicaldermatology.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned